NCT01519817. An Open Label Phase I Study to Evaluate the Safety and Tolerability of GI-6301 Vaccine Consisting of Whole, Heat -Killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express Brachyury Protein in Adults W ith Solid Tumors. 34. NCT02179515. An Open Label Phase I Study to Evaluate the Safety and Tolerability of a Modified Vaccinia Ankara (MVA) Based Vaccine Modified to Express Brachyury and T -Cell Costimulatory Molecules (MVA Brachyury -TRICOM). 35. Heery CR, Singh BH, Rauckhorst M, Marté JL, Donahue RN, Grenga I, et al. Phase I Trial of a Yeast -Based Therapeutic Cancer Vaccine (GI -6301) Targeting the Transcription Factor Brachyury. Cancer Immunol Res. 2015;3(11):1248 -56. 36. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323 -37. 37. Zaremba S, Barzaga E, Zhu M, Soares N, Tsang K Y, Schlom J. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 1997;57(20):4570 -7. 38. Yin L, Ahmad R, Kosugi M, Kufe T, Vasir B, Avigan D, et al. Survival of human multiple myeloma cells is dependent on MUC1 C -terminal transmembrane subunit oncoprotein function. Mol Pharmacol.